Key result
Dabigatran was successfully used as an alternative anticoagulant for 3 months after mitral valvuloplasty in a patient with warfarin resistance, without any embolic or bleeding complications.
Why the study?
Warfarin efficacy varies widely and may fail to achieve target PT-INR even at high doses, raising the question of using DOACs after mitral valvuloplasty in warfarin resistance.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Direct oral anticoagulants such as dabigatran may serve as a safe and effective alternative for postoperative anticoagulation in patients undergoing mitral valvuloplasty who exhibit warfarin resistance.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Wada et al. (2024) conducted a case report in Warfarin resistance after mitral valvuloplasty (n=1). Dabigatran vs. Warfarin (failed due to resistance) was evaluated on Embolism or bleeding complications. Dabigatran was successfully used as an alternative anticoagulant for 3 months after mitral valvuloplasty in a patient with warfarin resistance, without any embolic or bleeding complications.
Synapse has enriched 10 related papers. Consider them for comparative context: